Synthesis and Pharmacological Evaluation of Novel 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole Derivatives as Promising Anxiolytic and Analgesic Agents

Dmitriy V. Maltsev 1,2,*, Alexander A. Spasov 1,2,3,*, Pavel M. Vassiliev 1,3,*, Maria O. Skripka 1,2,*, Mikhail V. Miroshnikov 1, Andrey N. Kochetkov 3, Nataliya V. Eliseeva 1,*, Yuliya V. Lifanova 1, Tatjana A. Kuzmenko 4, Lyudmila N. Divaeva 4 and Anatoli S. Morkovnik 4

1 Department of Pharmacology and Bioinformatics, Volgograd State Medical University, 400131 Volgograd, Russia; aspasov@mail.ru (A.A.S.); pvassiliev@mail.ru (P.M.V.); rete.mirabile.renis@gmail.com (M.O.S.); mikhailiroshnikov@rambler.ru (M.V.M.); nvkirillova@rambler.ru (N.V.E.); imjerry@mail.ru (Y.V.L.)
2 Laboratory of Experimental Pharmacology, Volgograd Medical Scientific Center, 400131 Volgograd, Russia
3 Laboratory for Information Technology in Pharmacology and Computer Modeling of Drugs for Reasearch Center of Innovative Medicines, Volgograd Medical Scientific Center, 400131 Volgograd, Russia; akocha@mail.ru
4 Research Institute of Physical and Organic Chemistry, Laboratory of organic synthesis, Southern Federal University, 344090 Rostov-on-Don, Russia; takuzmenko@sfedu.ru (T.A.K.); divaevan@mail.ru (L.N.D.); asmork2@ipoc.sfuedu.ru (A.S.M.)
* Correspondence: maltsevdmitriy@rambler.ru; Tel.: +7961071-12-50

Abstract: A number of novel 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole derivatives were obtained by alkylation mainly in the 1H-tautomer form of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazo or its 8,9-dimethyl-substituted analog 4-chlorobenzyl bromide, 4-chloroaetic acid fluoroanilide, and 4-tert-butylphenacyl bromide in neutral medium. Compounds 3 were cywizarded and synthesized earlier with 11-phenacyl-substituted diazepino[1,2-a]benzimidazoles upon heating in conc. HBr. The chemical structures of the compounds were clarified by using the 1H Nuclear Magnetic Resonance Spectroscopy (1H-NMR) technique. Anxiolytic properties were evaluated using the elevated plus maze (EPM) and open field (OF) tests. The analgesic effect of compounds was estimated with the tail flick (TF) and hot plate (HP) methods. Besides, possible the influence of the test compounds on motor activities of the animals was examined by the Grid, Wire, and Rotarod tests. Compounds 2d and 3b were the most active due to their prominent analgesic and anxiolytic potentials, respectively. The results of the performed experiments showed that the high anxiolytic activity of compound 3b is explained by the combination of a pronounced interaction mainly with the benzodiazepine site of the GABA\(_A\) receptor with a prominent interaction with both the specific and allosteric sites of the 5-HT\(_{2A}\) receptor.

Keywords: diazepino[1,2-a]benzimidazole; triazabenzo[ac]cyclcopenta[cd]azulenium; anxiolytic; analgesic; hot plate; open field; tail flick; elevated plus maze; docking analysis

1. Introduction

At present, the recognition of the unity of biological, psychological, and social components of some pathologies, such as anxiety disorders [1] and pain syndrome [2], in addition to their multifactorial etiology, has led to a significant increase in interest among researchers globally. It is well known that anxiety and fear are evolutionary mechanisms of self-defense and survival, in addition to the nociceptive system, which has an adaptive-limiting function [3]. Therefore, a low level of anxiety and pain sensitivity cannot only be perceived as an exclusively positive phenomenon, but it is also necessary to consider the degree of danger of such a state [4]. However, one should distinguish the background level of anxiety...
from pathological anxiety, the symptoms of which include irritability, tension and inability to relax, a feeling of “nervousness”, memory impairment, and sleep disturbance [5]. The somatic manifestations of anxiety are highly diverse and include chronic pain of muscle hypertension, cardiovascular, and even pseudo-allergic symptoms [6]. According to Gal et al. [7], there is feedback between chronic pain syndrome and the formation of anxiety, depression, and sleep disturbance: it is necessary to combine analgesics and anxiolytics to correct these conditions [8]. Despite the adaptive function of pain, the chronic nature of acute pain is not adaptive and leads to the development of clinical syndromes [9]. In turn, complaints of acute and chronic pain remain difficult to treat, and there is a need for new effective analgesics in clinical practice [2,10]. This is a consequence of the complexity and diversity of pain modulation mechanisms at the pathophysiological level [2], in which many different mediators and receptors are involved, in addition to the heterogeneity of pain syndromes and the unreliability of some preclinical pain models [10]. Furthermore, the different etiology of the subtypes of anxiety disorders is due to the low efficiency of the use of existing anxiolytics in a number of clinical cases [11].

In the course of a directed search for active substances among the chemical class of imidazobenzimidazole derivatives, a compound under the code RU-31 was identified, possessing 5-HT$_{2A}$-antagonistic and anti-anxiety properties [12,13]. The behavioral activity of animals under the influence of compound RU-1276 with 5-HT$_3$-antagonistic action [14], with a single administration in the “Elevated Plus Maze” test, was characteristic of the action of anxiolytics (an increase both in the number of exits into the open arms of the EPM and the total time spent in them). In addition, compound RU-476, which has a 5-HT$_{2A}$ antagonistic effect, reduced the severity of anxious behavior in animals both in conflict conditions (Vogel conflict test) and a non-conflict (Elevated Plus Maze) stressful situation, which is comparable to the effect of diazepam [15]. For 2-mercaptobenzimidazole derivatives under the code AZH-57-67, an anxiolytic action was shown in Elevated Plus Maze and Open Field tests [16]. Derivatives of 2-aminomethylbenzimidazole showed high analgesic and anti-inflammatory activity in the models “Acetic acid-induced writhing” and “Carrageenan-induced paw edema” in mice, comparable to nimesulide at a dose of 50 mg/kg [17–19]. Compound RU-1205 is a new highly selective central kappa-opioid agonist, for which an analgesic activity has been previously shown [20], with antiepileptic and anticonvulsant components, confirmed in isolated experiments with maximal electroshock neurons [21]. The anxiolytic potential of benzodiazepine derivatives has been confirmed by many years of clinical practice, and according to the data of modern research, the neuropsychotropic properties of these compounds are used in many areas of medical science. According to the literature, some diazepine derivatives (TR) have analgesic activity by modulating TRPV1 receptors [22]. The selective agonist of GABA$_A$ receptors, acting mainly on the $\alpha_2/3$ subunit, KRM-II-81, exhibits not only anxiolytic and anticonvulsant effects in standard methods, but also analgesic activity in the formalin test [23].

In previous studies, the anxiolytic potential of diazepino[1,2-$\alpha$]benzimidazole derivatives has been shown [24]. As a product of a combination of privileged benzimidazole and diazepine scaffolds, these derivatives have an anti-anxiety effect that is superior to that of diazepam at an equimolar dose, and less of the pronounced side effects of classical benzodiazepines, such as muscle relaxation, addiction, and daytime sleepiness [25,26]. For example, an anti-anxiety activity has been shown for a number of diazepino[1,2-$\alpha$]benzimidazoles [24], including 11-$p$-fluorophenacyl- and 11-pyrrolidinoethylbenzimidazoles. It was found that compound DAB-19 exhibits pronounced anxiolytic activity in the Elevated Plus Maze test [25], in addition to an anticonvulsant effect in the “Pentylenetetrazole-induced seizures” model [27]. In addition, compound DAB-31 has analgesic and anxiolytic activities (Table 1) [28,29].

Thus, it was of interest to us to conduct a primary screening study for the anti-anxiety and analgesic activity of 11-substituted-2,3,4,5-tetrahydro[1,3]diazepino[1,2-$\alpha$]benzimidazole (2a-d) and already known peri-condensed analogs (3a–e) of this tricyclic system (Scheme 1, Table 2) [30].
Table 1. Chemical structures of described compounds.

| Chemical Structure | Name       |
|--------------------|------------|
| ![RU-31](image)    | RU-31      |
| ![RU-1276](image)  | RU-1276    |
| ![RU-476](image)   | RU-476     |
| ![AZH-57](image)   | AZH-57     |
| ![AZH-58](image)   | AZH-58     |
| ![AZH-59](image)   | AZH-59     |
| ![AZH-60](image)   | AZH-60     |
| ![AZH-61](image)   | AZH-61     |
| ![AZH-62](image)   | AZH-62     |
| ![AZH-63](image)   | AZH-63     |
| ![AZH-64](image)   | AZH-64     |
| ![AZH-65](image)   | AZH-65     |
| ![AZH-66](image)   | AZH-66     |
| ![AZH-67](image)   | AZH-67     |
| ![RU-1205](image)  | RU-1205    |
| ![TR](image)       | TR         |
| ![KRM-II-81](image)| KRM-II-81  |
| ![DAB-19](image)   | DAB-19     |
| ![DAB-31](image)   | DAB-31     |

Scheme 1. Synthesis of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole derivatives 2a–d, 3a–e.
Table 2. Radicals R, R¹ of compounds 2a–d, radicals R, Ar of compounds 3a–e.

| Compound | R   | R¹ | Compound | R   | Ar       |
|----------|-----|----|----------|-----|----------|
| 2a       | H   |    | 3a       | H   |          |
| 2b       | H   |    | 3b       | H   |          |
| 2c       | CH₃ |    | 3c       | H   |          |
| 2d       | H   |    | 3d       | CH₃ |          |
| 3e       | CH₃ |    |          |     |          |

2. Results and Discussion
2.1. Chemistry

Compounds 2a–d were obtained by alkylation of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole (1a) and its 8,9-dimethylsubstituted analogue (1b) with 4-chlorobenzyl bromide (for 2a), 4-chloroacetic acid fluoroanilide (for 2b,c) and 4-tert-butylphenacyl bromide (for 2d) in a neutral medium. Compounds 3a–e were synthesized earlier by cyclization of 11-phenacysubstituted diazepinobenzimidazoles upon heating in conc. HBr.

2.2. Pharmacology
2.2.1. Elevated Plus Maze Test

In the EPM test, in terms of the time spent in the open arms, the effect of all compounds under codes 2 and 3 significantly exceeded that for the control group; however, statistically significant differences were not observed in comparison with diazepam (Figure 1). Furthermore, after the introduction of ketone 2d, the number of animal entries into the open arm did not increase. The reactivity time of mice, which characterizes the animal’s initial decision rate and the degree of its inhibition, was statistically significantly reduced relative to the control under the action of compounds 2b, c, and 3d. For the entire line of substances, the decision time was shortened compared to diazepam. The total number of transitions was also increased for the entire series of compounds, both in relation to the control and to the diazepam, which may indicate a certain stimulating effect of the substances on the animals’ locomotor activity. The number of overhangs, as an additional anxiolytic parameter, was significantly higher for all diazepino[1,2-a]benzimidazoles 2 and 3 compared to controls, and for most relative to the comparison drug. The number of boluses, as the indicator of the animals’ emotional state, was decreased and was at the level of diazepam, which may indicate an animal’s calmer behavior.

2.2.2. Open Field and Spontaneous Locomotor Activity Assessment

In the OF test, the locomotor activity of mice was higher under the influence of all compounds, except 3b, compared with controls (Figure 2). Under the influence of diazepam, due to its muscle relaxant effect, the locomotor activity was generally less intense than that in the group of control animals. The number of times the animals reared under the influence of 3d remained at the level of the control values. The use of compounds 2c, d, and 3 led to an increase in the search activity compared with the control group, which does not exclude their influence on the cognitive functions of experimental animals. In general, there was a slight decrease in the number of short self-grooming acts associated with anxiety, and an increase in the number of long-term self-grooming acts, reflecting the comfortable, calm behavior of the animal. The number of entries to the illuminated center of the OF test remained at the level of control values under the action of compounds 2a, 3a,
and 3e. The muscle relaxation effect of compounds 2 and 3 was not indicated in Rotarod, Grid, and Wire tests in comparison with the controls (Figure 3), except for chlorobenzyl derivative 2a, which significantly reduced the mice retention time on the rotating rod relative to the control group in the Rotarod test ($p \leq 0.05$).

Figure 1. Anxiolytic activity in compounds 2 and 3 in Elevated Plus Maze test in comparison with diazepam (2 mg/kg), mice, per oral administration, $M \pm$ SEM: (a) number of entries to open arms of EPM; (b) time spent in open arms; (c) number of overhangs; (d) total number of transitions between arms of EPM. Note: * Data are comparable to the control group ($p \leq 0.05$, Kruskal–Wallis test post-hoc Dunn’s test); # The dose is equimolar to diazepam at a dose of 2 mg/kg.

2.2.3. Tail-Flick Test

According to the results of the TF test for diazepino[1,2-$\alpha$]benzimidazole derivatives 2 and 3, the analgesic activity of varying severity was shown. No analgesic effect was shown for substances 2a, c and 3b. Thus, after the introduction of these compounds, the observed indicator remained at the level of control values ($4.2 \pm 0.09$ s), and the value of the MPE did not exceed 10%. In the groups of animals treated with compounds 2b, d, 3a, c–e, there was a statistically significant increase in the latent period of tail flicker compared with the control group, which suggests the presence of an analgesic effect for the studied compounds; however, statistically significant differences from the butorphanol group were not observed. In addition, the maximum possible effect from the administration of compounds 3d, e was 1.8 times higher than the MPE of the reference drug butorphanol.
Data on the analgesic activity of the studied compounds in the TF test are presented in Figure 4.

Figure 2. Behavioral activity in compounds 2 and 3 in Open Field test in comparison with diazepam (2 mg/kg), mice, per oral administration, M ± SEM; (a) locomotor activity of animals; (b) rearing score; (c) reactivity time; (d) number of holes explored; (e) number of entries to the center of open field; f) number of long self-grooming acts Note: * Data are comparable to the control group (p ≤ 0.05, Kruskal–Wallis test post-hoc Dunn’s test); # The dose is equimolar to diazepam at a dose of 2 mg/kg.

2.2.4. Hot Plate Test

According to the results of the HP test, an increase in the latent period of licking the hind paw was noted for all experimental groups. The indices of compounds 2a, 3a, d were
inferior to the group of the comparison drug; in groups 2b, 3b, c, e the values of the latent period of licking of the hind paw were determined at the level of butorphanol. Significant differences from the control values and superiority over the comparison drug group were established in groups 2c, d. Data on the analgesic activity of the compounds under study in the HP test are presented in Figure 4.

Figure 3. Muscle relaxant activity in compounds 2 and 3 in Rotarod test in comparison with diazepam (2 mg/kg), mice, per oral administration, M ± SEM. Note: * Data are comparable to the control group (p ≤ 0.05, Kruskal–Wallis test post-hoc Dunn’s test); # The dose is equimolar to diazepam at a dose of 2 mg/kg.

Figure 4. Analgesic activity in compounds 2 and 3 in Tail Flick and Hot Plate tests in comparison with butorphanol (1 mg/kg), mice, i.p. administration, M ± SEM; (a) tail-flick latency; (b) %MPE of tail-flick; (c) licking a hind paw latency; (d) %MPE of hot plate. Note: * Data are comparable to the control group (p ≤ 0.05, one-way ANOVA, post-hoc Dunnett’s test); # The dose is equimolar to butorphanol at a dose of 1 mg/kg.
2.2.5. Structure–Activity Relationships of Compounds 2 and 3

According to the results of the screening study for diazepino[1,2-α]benzimidazole derivatives 2 and 3, it was shown that these derivatives have anxiolytic and analgesic effects of varying severity. Among 11-substituted diazepino[1,2-α]benzimidazoles, ketone 2d and amide 2b exhibited the highest analgesic activity. Amide 2c, a close analogue of compound 2b, containing methyl groups at positions 8 and 9, and chlorobenzyl derivative 2a, did not show a pronounced analgesic effect. Based on the data obtained, it is possible to construct a gradation of the analgesic effect: 2d > 2b > 2c > 2a, from which it follows that the presence of a phenacyle fragment substituted in the phenyl nucleus by a non-polar tert-butyl radical in 2d significantly enhances the analgesic properties, and upon substitution in this position for Cl or F atoms, the activity decreased. The introduction of methyl groups at positions 8 and 9 (2c) did not affect the level of analgesic activity. In the HP test, the MPE (%) for compound 2 was calculated at the level of, or even higher than, the reference drug butorphanol, which may indicate the predominant effect of compounds 2 on the supraspinal mechanisms of pain regulation.

Furthermore, the introduction of substances 2a–d led to the development of an anxiolytic effect, which statistically significantly exceeded the indicators of the control group in terms of the time spent in the open arms of the EPM; however, it did not reach the level of diazepam. By the parameter of the number of entries into open arms of the EPM for compounds 2a–c, the level of control values was statistically significantly exceeded, also exceeding the indices of diazepam for 2a, c. In terms of the number of overhangs, all compounds of this series showed an effect that was not inferior than that for diazepam, and had a psychostimulating effect on mice in terms of locomotor activity and the number of times the mice reared in the OF compared to the control group. Thus, the presence of Cl and F radicals in the phenyl nucleus of the phenacyl fragment of structures 2a and 2c had a positive effect on the anti-anxiety effect of the substances, in contrast to the pattern previously identified for analgesic properties.

Among the peri-cyclic structures 3, the highest analgesic effect was observed when compound 3e was administered to mice, which contained a fluorine atom in the ary1 substituent and methyl groups in the phenyl nucleus. The replacement of the fluorine atom with the hydroxyl group in the structure of substance 3a and the methyl groups for hydrogen atoms led to a decrease in the analgesic effect compared to 3e. Nevertheless, in the TF test, 3a exhibited an activity that was statistically significantly higher than the control values and slightly higher than that of butorphanol, in addition to 3c, which, like 3a, contains hydrogen atoms in the phenyl nucleus, but a biphenyl substituent at position 4 instead of hydroxyphenyl. Compound 3b, 4-fluorosubstituted at the ary1 radical, in contrast to hydroxysubstituted 3a, did not show an analgesic effect in the TF test. The structural analogue of the most active compound 3e under the code 3d, which differs by a hydroxyl substituent instead of the F atom of the ary1 radical, in turn, did not show pronounced analgesic activity in the HP test. According to the results of calculating the MPE (%), in the TF test in compounds 3, all compounds, excluding 3b, exhibited an effect at the level of butorphanol, which may indicate the effect of compounds 3 on the spinal mechanisms of nociception.

Compounds 3a–d showed a statistically significant difference from the control group in terms of time and number of entries into the open arms of the EPM, in addition to the number of overhangs. At the same time, only the level of anti-anxiety action of fluorophenyl derivative 3b, which did not show an analgesic effect in TF and HP tests, corresponded to the reference drug diazepam. For compound 3b, there was also no statistically significant increase in the motor activity in the OF compared to the control, and the number of entries to the center of the OF was doubled relative to diazepam, which is a positive criterion for positioning 3b as a new anxiolytic. For oxyphenyl derivative 3a, a close structural analogue of 3b with moderate analgesic properties, the time spent by the animals in the open arms of the EPM installation decreased 2–3 times compared with 3b. The anti-anxiety effect of substance 3e, which showed the most pronounced analgesic properties in compounds
was found to be low, and in terms of the time spent by animals in open arms, did not exceed the control values.

### 2.2.6. In Silico Analysis

In order to detail the targeted nature of the anxiolytic effect of the most active compound 3b, an in silico analysis of the molecular binding mechanism to the GABA-binding and benzodiazepine sites of the GABA<sub>A</sub> receptor, as well as to the specific and allosteric sites of the 5-HT<sub>2A</sub> receptor, was carried out in comparison with diazepam and ketanserin reference drugs, respectively.

The calculated values of the docking energies and binding constants of the studied compounds are shown in Table 3.

#### Table 3. Docking energies and binding constants of compound 3b and reference drugs for the sites of GABA<sub>A</sub> and 5-HT<sub>2A</sub> human receptors.

| Compound | GABA<sub>A</sub> Receptor | 5-HT<sub>2A</sub> Receptor |
|----------|---------------------------|---------------------------|
|          | GABA Site | Benzodiazepine Site | Specific Site | Allosteric Site | GABA Site | Benzodiazepine Site | Specific Site | Allosteric Site |
|          | ∆E, kcal/mol | K, nM | ∆E, kcal/mol | K, nM | ∆E, kcal/mol | K, nM | ∆E, kcal/mol | K, nM |
| 3b       | −7.5    | 3410   | −10.8    | 13.4   | −9.7    | 84.9   | −11.1    | 8.1 |
| diazepam | −7.1    | 6674   | −9.8    | 71.8   | −8.5    | 637    | −9.3     | 166 |
| ketanserin | —      | —      | —       | —      | −9.9    | 60.7   | −11.1    | 8.1 |

According to the data in Table 3, compound 3b preferentially interacts with the benzodiazepine site of the GABA<sub>A</sub> receptor, with a lower affinity for its GABA-binding site.

Compared to 3b, diazepam, in terms of binding constants, interacts 5.4 times weaker with the benzodiazepine site of the GABA<sub>A</sub> receptor and 2 times weaker with its GABA-binding site.

In addition, in accordance with the obtained ∆E and K values, compound 3b interacts very intensively with the 5-HT<sub>2A</sub> receptor; in terms of its affinity, 3b is practically comparable to ketanserin.

At the same time, diazepam exhibits a significantly lower affinity for the 5-HT<sub>2A</sub> receptor: in comparison with ketanserin, in terms of binding constant values, it interacts 10.5 times weaker with the specific site of 5-HT<sub>2A</sub> and 20.5 times weaker with its allosteric site.

Thus, according to in silico data, compound 3b should have a higher anxiolytic activity than diazepam, which is due to the significantly higher affinity of 3b, in comparison with diazepam, to both the benzodiazepine and GABA-binding sites of the GABA<sub>A</sub> receptor, as well as a very pronounced 5-HT<sub>2A</sub> antagonistic action comparable to that of ketanserin and significantly greater than the serotonergic action of diazepam.

The comparison of the binding pattern with the benzodiazepine and GABA-binding sites of the GABA<sub>A</sub> receptor for compound 3b and the reference drug diazepam is shown in Figure 5.

Comparison of the binding sites reveals that 3b and diazepam have very similar mechanisms of binding to the benzodiazepine site: five of the six amino acids involved in interactions are common: PHE757D, TYR817D, TYR867D, TYR1477E, and PHE1496E. TYR1477E participates both in the electrostatic interaction with nitrogen of the diazepine ring and in the hydrophobic interaction with the fluorophenyl fragment in the case of 3b, and in the case of diazepam, only in the hydrophobic interaction with the Cl substituent. PHE1496E is involved only in hydrophobic interactions in the case of 3b, and in the case of diazepam, both hydrophobic interactions and pi-stacking. MET1549E is involved in hydrophobic binding in 3b, which is not characteristic of diazepam.

In the case of the GABA-binding site, both 3b and diazepam molecules exhibit numerous hydrophobic interactions. The similar binding mechanism of 3b and diazepam is confirmed by the presence of four common binding amino acids: LEU785D, THR829D,
THR783D, and ALA1871K. THR779D and TYR1850K are involved in hydrophobic binding in 3b, while in diazepam, it is only THR1199C.

![Diagram](image_url)

**Figure 5.** The nature of the binding of compounds in the sites of the GABA<sub>A</sub> receptor: (a) benzodiazepine site; (b) GABA-binding site.

The higher affinity of 3b compared to diazepam is probably due to the greater number of hydrophobic interactions and strong electrostatic interactions and, as a result, higher total energy.

Consideration of the spatial arrangement of these two compounds at the benzodiazepine site of the GABA<sub>A</sub> receptor shows that 3b is characterized by four-center binding, while only three interaction centers are involved in diazepam fixation. These features provide a stronger fixation of the 3b molecule in the site, which leads to a higher activity of this compound. At the GABA-binding site, the spatial arrangement of 3b and diazepam is approximately the same and for both molecules, is due to three-center hydrophobic binding (Figure 6).

Comparison of the binding pattern with the specific and allosteric sites of the 5-HT<sub>2A</sub> receptor for compound 3b and the reference ketanserin is shown in Figure 7.

The ketanserin and 3b molecules include fluorinated phenyl, which provides hydrophobic interactions with the same identical seven amino acids at a specific 5-HT<sub>2A</sub> site. Thus, in this area of interaction, the binding mechanisms of 3b and ketanserin are the same.

The second benzene ring in the ketanserin structure is stacked and provides hydrophobic interactions, which seem to provide some greater affinity of ketanserin for the specific site 5-HT<sub>2A</sub>, compared to 3b.
Figure 6. Location of the compounds in the GABA<sub>A</sub> receptor sites; (a) benzodiazepine site; (b) GABA-binding site.

Figure 7. The nature of the binding of compounds at the sites of the 5-HT<sub>2A</sub> receptor; (a) specific site; (b) allosteric site.
In the case of the allosteric site of the 5-HT\textsubscript{2A} receptor, the binding mechanisms of 3b and ketanserin are practically the same: both molecules have two broad regions of hydrophobic interactions by means of six common binding amino acids.

The spatial arrangement of these two compounds at the specific site of the 5-HT\textsubscript{2A} receptor is approximately the same and confirms the assumptions made: 3b has three regions of hydrophobic interaction, while ketanserin has three regions of hydrophobic interaction and pi-stacking. However, in both cases, three-center binding is observed. In the allosteric site of 5-HT\textsubscript{2A}, the spatial arrangement of 3b and ketanserin is also approximately the same and for both molecules, is due to three-center hydrophobic binding (Figure 8).

![Figure 8. Arrangement of compounds at the sites of the 5-HT\textsubscript{2A} receptor: (a) specific site; (b) allosteric site.](image)

The results of the performed in silico analysis with a high degree of probability allow us to assert that the high anxiolytic activity of compound 3b is explained by the combination of a pronounced interaction mainly with the benzodiazepine site of the GABA\textsubscript{A} receptor with a prominent interaction with both the specific and allosteric sites of the 5-HT\textsubscript{2A} receptor.

### 3. Materials and Methods

#### 3.1. General Procedure for the Synthesis of Compounds 2

Compounds 2a–d were obtained by alkylation mainly in the 1H-tautomeric form of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-\textalpha]benzimidazole (1a) [31] or its 8,9-dimethylsubstituted analog (1b) 4-chlorobenzyl bromide, 4-chloroacetic acid fluoroanilide, and 4-\text{tert}-butylphenacyl bromide in neutral medium. Compounds 3a–e were cyclized and synthesized earlier [30] with 11-phenacylsubstituted diazepino[1,2-\textalpha]benzimidazoles upon heating in conc. HBr.

#### 3.1.1. 11-(4-chlorobenzyl)-2,3,4,5-tetrahydro[1,3]diazepino[1,2-\textalpha]benzimidazole Hydrochloride (2a)

A solution of 1.87 g (10 mmol) of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-\textalpha]benzimidazole (1a) and 1.60 g (10 mmol) of 4-chlorobenzyl chloride in 10 mL of nitromethane was boiled for 5 h. After cooling, the separated precipitate was filtered, washed with acetone. Yield 3.12 g (90%). Colorless crystals, m.p. 231–232 °C (was recrystallized from EtOH).\textsuperscript{1}H NMR
spectrum (300 MHz), δ, ppm (DMSO-d$_6$): 1.96–2.10 (m, 4H, C(3)H$_2$, C(4)H$_2$), 3.56–3.58 (m, 2H, C(2)H$_2$), 4.32–4.36 (m, 2H, C(5)H$_2$), 5.47 (s, 2H, CH$_2$Ar), 7.30–7.42 (m, 7H, H(8), H(9), H(10) or H(7), H(2'), H(3'), H(5'), H(6')) (Hereinafter, numbers with a stroke show the protons of the aryl substituent in position 11 of diazepinobenzimidazole 1), 7.71 (d, 1H, J = 7.5), 8.99 (s, 1H, +NH). Found, (%): C 62.34; H 5.21; Cl 20.00; N 12.36. C$_{18}$H$_{18}$ClN$_3$. Calculated, (%): C 62.08; H 5.50; Cl 20.36; N 12.07 (Figure 9).

Figure 9. Compound 2a.

3.1.2. N-(4-fluorophenyl)-2-(2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazol-11-yl)acetamide Hydrochloride (2b)

A solution of 0.38 g (2 mmol) of diazepinobenzimidazole 1a and 0.38 g (2 mmol) of 4-fluoroanilide of chloroacetic acid in 5 mL of nitromethane was boiled for 6 h, cooled, 5 mL of diethyl ether was added, and the precipitate that formed was filtered off and washed with acetone. Yield 0.57 g (75%). Colorless crystals, m.p. 231–232°C (was recrystallized from CH$_3$CN). $^1$H NMR spectrum, (600 MHz), δ, ppm (DMSO-d$_6$): 1.98–2.09 [m, 4H, C(3)H$_2$, C(4)H$_2$], 3.52–3.46 [m, 2H, C(5)H$_2$], 4.34–4.35 [m, 2H, C(2)H$_2$], 5.22 (s, 2H, CH$_2$CO), 7.16 [t, 2H, H(8), J = 8.7 Hz], 7.33–7.39 [m, 2H, H(2'), H(6')], 7.60 (d, 1H, H(10), J = 8.0 Hz), 7.62–7.65 [m, 2H, H(3'), H(5')], 7.69 [d, 1H, H(7), J = 7.8 Hz], 9.62 (s, 1H, NHCO), 10.96 (s, 1H, +NH). Found, (%): N 19.68. C$_{19}$H$_{19}$FN$_4$O HCl. Calculated, (%): N 19.95 (Figure 10).

Figure 10. Compound 2b.

3.1.3. N-(4-fluorophenyl)-2-(8,9-dimethyl-2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazol-11-yl)acetamide Hydrochloride (2c)

This compound was prepared analogously to compound 2b from 8,9-dimethyldiazepinobenzimidazole 1b and chloroacetic acid 4-fluoroanilide in 79% yield. Colorless crystals, m.p. 260–262°C (was recrystallized from propanol-2). $^1$H NMR spectrum, (600 MHz), δ, ppm (DMSO-d$_6$): 1.95–2.04 [m, 4H, C(3)H$_2$, C(4)H$_2$], 3.29 (s, 3H, CH$_3$), 2.31 (s, 3H, CH$_3$), 3.47–3.52 [m, 2H, C(5)H$_2$], 4.25–4.27 [m, 2H, C(2)H$_2$], 5.18 (s, 2H, CH$_2$CO), 7.14–7.17 [m, 2H, H(2'), H(6')], 7.40 [s, 1H, H(10)], 7.49 [s, 1H, H(7)], 7.63–7.65 [m, 2H, H(3'), H(5')], 9.12 (s, 1H, NHCO), 10.97 (s, 1H, +NH). Found, (%): N 13.67. C$_{21}$H$_{23}$FN$_4$O HCl. Calculated, (%): N 13.91 (Figure 11).
3.1.4. 11. -(4-tert-butylphenyl)-2-(2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazol-11-yl)ethanone Hydrobromide (2d)

A solution of 1.87 g (10 mmol) of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole 1a and 2.55 g (10 mmol) of 4-tert-butylphenacyl bromide in 10 mL of acetonitrile was boiled for 10 h. After cooling, the separated precipitate was filtered off and washed with acetone. Yield 3.75 g (85%). Colorless crystals with m.p. 217–220 °C (was recrystallized from CH₃CN).¹H NMR spectrum, (600 MHz), δ, ppm (DMSO-d₆): 1.31 [s, 9H, C(CH₃)₃], 1.92–1.95 [m, 2H, C(3)H₂], 2.05–2.08 [m, 2H, C(4)H₂], 3.44–3.46 [m, 2H, C(5)H₂], 4.34–4.35 [m, 2H, C(2)H₂], 5.94 (s, 2H, CH₂COAr), 7.32 (t, 1H, H(8) or H(9), J = 7.4 Hz), 7.35 (t, 1H, H(9) or H(8), J = 7.8 Hz), 7.59 (d, 1H, H(10), J = 8.0 Hz), 7.63 (d, 2H, H(3'), H(5'), J = 8.5 Hz), 7.70 (d, 1H, H(7), J = 7.8 Hz), 7.99 (d, 2H, H(2'), H(6'), J = 8.5 Hz), 8.77 (s, 1H, +NH). Found, (%): C 62.02; H 6.04; Br 18.31; N 9.23. C₂₃H₂₇BrN₃O·HBr. Calculated, (%): C 62.44; H 6.38; Br 18.06; N 9.50 (Figure 12).

4. Experimental Procedure

4.1. Animals

The experiments were carried out on 330 adult male BALB/c mice, with an average weight of 18–25 g. Mice were randomly divided into equal groups of 6 animals. The animals were kept in a vivarium with a 12/12 light/dark cycle on a standard food diet for laboratory animals without restriction of access to food and water, in compliance with the International Recommendations for the Protection of Vertebrates Used in Experimental Research (2017). The performance of the work corresponds to the parameters for preclinical studies (Order of the Ministry of Health of Russia dated 04.01.2016 N 199n “On the approval of the Rules of Good Laboratory Practice”, registered with the Ministry of Justice of Russia on 08.15.2016 N 43232).

4.2. Drugs and Treatment

Diazepino[1,2-a]benzimidazoles 2 and 3 were synthesized by the Research Institute of Physical and Organic Chemistry, Southern Federal University, Rostov-on-Don, Russia. The control groups were injected with a solvent (distilled water) in an equivalent volume of 0.1 mL per 10 g of an individual’s weight. The animals of the reference drug groups received diazepam (J.S.C. Polfa, Poland) at a dose of 2 mg/kg [29] and butorphanol (FSUE “Moscow Endocrine Plant”, Russia) at a dose of 1 mg/kg [20]. Substances of groups 2
and 3 were injected per oral with an atraumatic metal probe 30 min before the start of the experiments. Their doses were calculated equimolar to the comparison drug diazepam (2 mg/kg) in the Elevated Plus Maze, Open Field, Rotarod, Grid and Wire tests. For the Tail Flick and Hot Plate tests, compounds were administered i.p. to mice 60 min before the start of the experiments, and doses 2 and 3 were calculated equimolar to the reference drug butorphanol (1 mg/kg).

4.3. Anxiolytic Assay

The anxiolytic activity of the compounds was studied in the Elevated Plus Maze test [32]. The mouse was placed in the center of the installation with its head towards the open arm; the observation time for each animal was 5 min. The following parameters were recorded: reactivity—the time of the first exit of the animal from the center of the installation (s), the number of transitions between the arms, the time spent in open arms (s), the number of entries into open arms, the number of overhangs, and the number of fecal boluses.

The study of animal’s behavior was carried out in an Open Field test [33]. During 5 min of the test, the locomotor activity (the number of crossed quadrants) and the number of times the animal reared, in addition to the search activity (represented by the number of times the animal peeped into the holes), the animals’ reactivity time (the time of leaving the central segment, s), the number of entries to the center of arena, and the number of acts of short (less than 5 s) and long (more than 5 s) self-grooming were recorded.

4.4. Analgesic Assay

The search for analgesic-active compounds was carried out in Tail Flick and Hot Plate tests (UgoBasile, Varese, Italy) [34]. In the first test, the tail withdrawal time (s) from thermal stimulation (55 °C) was estimated; in the second test, the animal was placed on a plate heated to 55 °C surrounded by a transparent cylinder, and then the latent time of the first licking of the hind paw was recorded (s). To avoid the risk of damage to animal tissue, the maximum duration of thermal exposure was limited to 15 s in the Tail Flick test and 30 s in the Hot Plate test.

For each group of studied substances, the value of the maximum possible effect (MPE, %) was determined, calculated by the formula [35,36]:

\[
MPE (\%) = \left( \frac{LP_2 - LP_1}{MAX_{TIME} - LP_1} \right) \times 100\%
\]  

(1)

where \(LP_2\) is the latent period of the reaction after the administration of the substance, \(LP_1\) is the latent period of the reaction before the administration of the substance, and \(MAX_{TIME}\) is the maximum time of the stimulus application.

4.5. Muscle Relaxant Properties

The study of muscle relaxant effects of substances was carried out in Rotarod, Grid, and Wire tests [29]. The Rotarod device is a rod with a diameter of 2.5 cm rotating at a constant speed of 10 rpm. The mouse was placed on the rod and the retention time on it was recorded—maximum 30 s. For the Grid test, the animals were placed on a horizontal grid from the bottom side (upside down). During 30 s of the test, the number of paws used by the animals for holding was recorded. Similar indicators were recorded for the Wire test, where the animals had to pull themselves up on a wire, which they held with two paws. The Grid and Wire tests were assessed in points from 0 to 4 according to the number of paws involved.

4.6. In Silico Analysis

Construction of the optimized 3D-models of compounds was performed using molecular mechanics and quantum chemistry successively with programs MarvinSketch 17.1.23 [37] and MOPAC2016 [38].
Search for valid 3D-models of the most abundant α1-β2-γ2-GABA$_A$ subtype receptor and 5-HT$_{2A}$ receptor of *Homo sapiens* was conducted using a previously developed method [39]. For each biotarget, three such models were found: for the GABA$_A$ receptor, two experimental 6D6T, 6D6U [40] and one theoretical [41], for the 5-HT$_{2A}$ receptor also two experimental 6A93, 6A94 [40] and one theoretical 5d6b98e9c0432ae919177b2b38d636c [42].

Ensemble docking was performed using the AutoDockVina 1.1.2 program [43], each compound in 10 conformers, 5 times in each site of each model, with the calculation of 150 obtained values of the minimum docking energies $\Delta E$, as described in [39]. The binding mechanism was analyzed using the LigandScout 4.1 program [44].

5. Statistical Analysis

Statistical processing of the obtained data *in vivo* was carried out using the Kolmogorov–Smirnov test with the Wilcoxon–Lilliefors test. In the case of normal distribution of the data, one-way ANOVA was used with Dunnett’s post-hoc test; for non-parametric statistics, the Kruskal–Wallis test and Dunn’s post-hoc test were used. Calculations were implemented in GraphPad Prism v.7.0. Results are presented as M ± SEM ($p \leq 0.05$).

6. Conclusions

1. Derivatives of diazepino[1,2-$a$]benzimidazole 2 and 3 showed anxiolytic and analgesic activities of varying severity.

2. The presence of the 2,3,4,5-tetrahydro[1,3]diazepino[1,2-$a$]benzimidazole fragment in the structure of the substances tends to manifest a moderate anxiolytic effect (2a–d) in terms of the time spent in the open arms of the EPM. According to the totality of anxiolytic parameters in the series 2a–d, chlorobenzyl derivative 2a and fluoro-phenylacetamide 2c were the most active. In Open Field, 2a–d had a psychostimulating effect. The presence of electronegative Cl and F atoms in the radical part of the structure of the compounds was found to be less favorable for analgesic activity than for anti-anxiety activity.

3. In compounds 3, according to the parameters characterizing the anxiety state of animals (the number of entries and time spent in open arms, the number of overhangs), the substances under the code 3a–e showed a statistically significant difference from the control group; however, the effect at the level of diazepam was shown only for the fluorophenyl derivative 3b. Administration of compounds 3a–e positively influenced the search activity of mice in Open Field.

4. For the analgesic action of compounds of series 2, the most effective was the substitution of (4-fluorophenyl)acetamide (2b) and 4-tert-butylphenacyl (2d), in addition to the hydrogen atoms in positions 8 and 9. Derivatives of 2 mainly affect the supraspinal regulation of pain, and 3 mainly affects the spinal regulation.

5. In compounds 3, the most significant aspect for the analgesic effects was the presence in the molecule of methyl substituents at positions 8 and 9, and a 4-fluorophenyl substituent of the core structure (3e). Compounds 3a and 3c, containing hydrogen atoms instead of methyl substituents (3e) and an aryl or hydroxyl substituent in the $p$-position of the phenyl radical, had a somewhat less pronounced analgesic effect.

6. According to the in silico study, 3b is characterized by the interaction with the GABA$_A$ receptor and by a prominent 5-HT$_{2A}$ antagonistic action.

Author Contributions: Conceptualization, D.V.M. and P.M.V.; Data curation, A.A.S.; Formal analysis, P.M.V. and M.V.M.; Funding acquisition, D.V.M.; Investigation, M.O.S., M.V.M., A.N.K., N.V.E. and Y.V.L.; Methodology, A.A.S., M.V.M. and N.V.E.; Project administration, D.V.M.; Resources, T.A.K., L.N.D. and A.S.M.; Software, A.N.K. and Y.V.L.; Supervision, D.V.M.; Validation, P.M.V.; Visualization, M.O.S.; Writing—original draft, M.O.S.; Writing—review & editing, M.O.S. All authors have read and agreed to the published version of the manuscript.

Funding: Synthesis of substances was financially supported by the Ministry of Science and Higher Education of the Russian Federation (State assignment in the field of scientific activity, Southern Fed-
eral University, 2020, project FENW-2020-0031 (0852-2020-0031). In vivo and in silico investigations, and the APC were funded by RFBR grant number 20-015-00164.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Volgograd State Medical University IRB 00005839 IORG 0004900 (OHRP) 02.17.2020.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** Synthesis of substances was financially supported by the Ministry of Science and Higher Education of the Russian Federation (State assignment in the field of scientific activity, Southern Federal University, 2020, project FENW-2020-0031 (0852-2020-0031). In vivo and in silico investigations, and the APC was funded by RFBR grant number 20-015-00164.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Samples of the compounds are available from the authors.

**References**

1. Bandelow, B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. *Adv. Exp. Med. Biol.* 2020, 1191, 347–365. [CrossRef]
2. Yekkirala, A.S.; Roberson, D.P.; Bean, B.P.; Woolf, C.J. Breaking barriers to novel analgesic drug development. *Nat. Rev. Drug Discov.* 2017, 16, 545–564. [CrossRef]
3. Morrison, I.; Perini, I.; Dunham, J. Facets and mechanisms of adaptive pain behavior: Predictive regulation and action. *Front. Hum. Neurosci.* 2013, 7, 755. [CrossRef]
4. Cimpean, A.; David, D. The mechanisms of pain tolerance and pain-related anxiety in acute pain. *Health Psychol. Open* 2019, 6, 205510291865161. [CrossRef] [PubMed]
5. Rosen, J.B.; Schulkin, J. From normal fear to pathological anxiety. *Psychol. Rev.* 1998, 105, 325–350. [CrossRef] [PubMed]
6. Gelenberg, A.J. Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment. *Clin. Psychiatry* 2000, 2, 49–54. [CrossRef]
7. Gal, Z.; Huse, R.J.; Gonda, X.; Kumar, S.; Juhasz, G.; Bagdy, G.; Petschner, P. Anxiety and depression—The role of blood-brain barrier integrity. *Neuropsychopharmacol. Hung.* 2019, 21, 19–25.
8. Davari, M.; Amani, B.; Amani, B.; Khanijahani, A.; Akbarzadeh, A.; Shabestan, R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: A systematic review and meta-analysis. *Korean J. Pain* 2019, 33, 3–12. [CrossRef]
9. Mifflin, K.A.; Kerr, B.J. The transition from acute to chronic pain: Understanding how different biological systems interact. *Can. J. Anaesth.* 2013, 61, 112–122. [CrossRef]
10. Bektas, N.; Nemutlu, D.; Arslan, R. The imidazoline receptors and ligands in pain modulation. *Indian J. Pharmacol.* 2015, 47, 472–478. [CrossRef] [PubMed]
11. Grieve, G.; Holmes, A. 50 years of hurdles and hope in anxiolytic drug discovery. *Nat. Rev. Drug Discov.* 2013, 12, 667–687. [CrossRef]
12. Sultanova, K.T.; Yakovlev, D.S.; Maltsev, D.V.; Miroshnikov, M.V.; Morkovina, Y.V.; Anisimova, V.A.; Morkovkin, A.S. Anxiolytic Properties of the RU-31 Compound. *Bull. Volgograd State Med. Univ.* 2018, 3, 28–32. [CrossRef]
13. Spasov, A.A.; Yakovlev, D.S.; Maltsev, D.V.; Zhukovskaya, O.N.; Anisimova, V.A.; Kovalev, G.I.; Zimin, I.A.; Morkovina, Y.V. The derivatives of imidazo[1,2-a]benzimidazole as 5-HT2A receptor antagonists. *Russ. J. Bioorg. Chem.* 2016, 42, 397–403. [CrossRef]
14. Yakovlev, D.S.; Lyubashina, O.A.; Busygina, I.I.; Maltsev, D.V.; Anisimova, V.A.; Zhukovskaya, O.N.; Morkovkin, A.S.; Spasov, A.A. Anisopasmodic and visceral analgesic effects of new 5-HT3 receptor antagonist emetazol in experiment. *Exp. Clin. Pharmacol.* 2018, 81, 8–12. [CrossRef]
15. Maltsev, D.V.; Yakovlev, D.S.; Matokhin, D.G.; Samsonik, Y.V.; Spasov, A.A.; Anisimova, V.A. P4-c.002 Anxiolytic action of a new 5-HT2A antagonist RU-476. *Eur. Neuropsychopharmacol.* 2013, 23, 519–520. [CrossRef]
16. Spasov, A.A.; Zhukovskaya, O.N.; Maltsev, D.V.; Miroshnikov, M.V.; Skripka, M.O.; Sultanova, K.T.; Morkovkin, A.S. Anxiolytic Activity of 11H-2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole and 2-Mercaptobenzimidazole Derivatives. *Russ. J. Bioorg. Chem.* 2020, 46, 107–114. [CrossRef]
17. Achar, K.C.; Hosamani, K.M.; Seetharamaredy, H.R. In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. *Eur. J. Med. Chem.* 2010, 45, 2048–2054. [CrossRef] [PubMed]
18. Keri, R.S.; Hiremathad, A.; Budagumpi, S.; Nagaraja, B.M. Comprehensive Review in Current Developments of Benzimidazole-Based Medicinal Chemistry. *Chem. Biol. Drug Des.* 2015, 86, 19–65. [CrossRef] [PubMed]
19. Cheretaev, I.V.; Korenyuk, I.I.; Nozdrachev, A.D. Neurotropic, Psychoactive, and Analgesic Properties of Benzimidazole and Its Derivatives: Physiological Mechanisms. *Neurosci. Behav. Physiol.* 2018, 48, 848–853. [CrossRef]
20. Spasov, A.A.; Grechko, O.Y.; Shtareva, D.M.; Rashchenko, A.I.; Eliseeva, N.V.; Anisimova, V.A. Analgesic activity of the kappa opioid receptor agonist—RU-1205 in rats. *J. Clin. Health Sci.* 2018, 2, 13–18. [CrossRef]
21. Kalitin, K.Y.; Spasov, A.A.; Grechko, O.Y.; Sukhov, A.G.; Vislobokov, A.I.; Anisimova, V.A.; Matukhno, A.E. Anticonvulsant and membranepromoting activity of RU-1205 compound. *Exp. Clin. Pharmacol.* 2017, 9, 28–34. [CrossRef]

22. Liu, Y.; Liao, C.; Zhou, J.; Liu, C.; Li, Q.; Jiang, Y.; Qian, H. Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1. *Biorg. Med. Chem.* 2018, 26, 4567–4573. [CrossRef]

23. Witkin, J.M.; Cerne, R.; Davis, P.G.; Freeman, K.B.; Carmo, J.M.D.; Rowlett, J.K.; Methuku, K.R.; Okun, A.; Gleason, S.D.; Li, X.; et al. The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats. *Pharmacol. Biochem. Behav.* 2019, 180, 22–31. [CrossRef]

24. Spasov, A.A.; Divaeva, L.N.; Maltsev, D.V.; Kuzmenko, T.A.; Morkovnik, A.S.; Miroshnikov, M.V.; Taran, A.S.; Zolotova, E.A. Anxiolytic potential of a new series of diazepinobenzimidazole derivatives. *Bull. Volgogr. State Med. Univ.* 2018, 3, 19–23. [CrossRef]

25. Taran, A.S.; Maltsev, D.V.; Yakovlev, D.S.; Karavaeva, T.V.; Tkachenko, Y.O.; Divaeva, L.N.; Morkovnik, A.S.; Kuzmenko, T.A. Study of anxiolytic activity in a series of new diazepinobenzimidazole derivatives using the “ElevatedPlusMaze” installation. *Volgogr. J. Med. Sci. Res.* 2017, 1, 24–26, [in Russian].

26. Divaeva, L.N.; Spasov, A.A.; Maltsev, D.V.; Kuzmenko, T.A.; Morkovnik, A.S.; Yakovlev, D.S.; Taran, A.S.; Petrov, V.I.; Anisimova, V.A. 11-(4-Tert-Butylbenzyl)- and Phenacyl-Substituted 2,3,4,5-Tetrahydro[1,3]Diazepino [1,2-a]Benzimidazoles, Possessing Anxiolytic Activity. Patent of Russia 2629022, 14 October 2016.

27. Divaeva, L.N.; Spasov, A.A.; Kuzmenko, T.A.; Maltsev, D.V.; Morkovnik, A.S.; Taran, A.S.; Petrov, V.I. 11-(4-Tert-Butylbenzyl)-2,3,4,5-Tetrahydro-[1,3]-Diazepino-[1,2-a]-Benzimidazole Hydrobromide and Triazabenzo[a]-Cyclopenta-[cd]-Azulene, Possessing Anxiolytic and Anticonvulsant Activity. Patent of Russia 2662242, 25 July 2017.

28. Divaeva, L.N.; Spasov, A.A.; Kuzmenko, T.A.; Morkovnik, A.S.; Yakovlev, D.S.; Taran, A.S.; Petrov, V.I.; Bogoslavtseva, M.V. 1-(3,4-Dimethoxyphenyl)-2-(7,8-Dimethyl-2,3,4,5-Tetrahydro-[1,3]Diazepino-[1,2-a]-Benzimidazol-11-yl) EthanoneHydrobromide, Possessing Analogic and Anxiolytic Activity. Patent of Russia 2636785, 1 December 2017.

29. Miroshnikov, M.V.; Divaeva, L.N.; Anisimova, V.A.; Morkovnik, A.S.; Skripka, M.O.; Zolotova, E.A.; Maltsev, D.V.; Spasov, A.A. Study of the anxiolytic activity of new diazepinobenzimidazole derivatives under the codes DAB-21 and DAB-31. *Exp. Clin. Pharmacol.* 2018, 81, 160–161.

30. Kuzmenko, T.A.; Morkovnik, A.A.; Divaeva, L.N.; Bogoslavtseva, M.V. Peri-Cyclization of 11-arylmethyl-2,3,4,5-tetrahydro-[1,3]-diazepinobenzimidazoles into 2-aryl-3,4,5,6-tetrahydro-2a,6a,10b-triazabenzo-[a]-cyclopenta-[cd]-azulenic bromides. *Russ. J. Org. Chem.* 2017, 53, 1253–1257. [CrossRef]

31. Morkovnik, A.S.; Spasov, A.A.; Kuzmenko, T.A.; Kucheryavenko, A.F.; Divaeva, L.N.; Koshchienko, Y.V.; Anisimova, V.A.; Kuzmina, L.G.; Rogova, N.V.; Kuznetsova, V.A.; et al. Prototropic equilibrium in 1(11)H-2,3,4,5-tetrahydro-[1,3]diazepino-[1,2-a]benzimidazol-11-yl) benzimidazol-4,5-dione possessing anxiolytic and pharmacological properties of its N-substituted derivatives. *Russ. Chem. Bull.* 2015, 64, 2622–2631. [CrossRef]

32. Voronina, T.A.; Seredenin, S.B.; Yarkova, M.A.; Voronin, M.V. Methodological recommendations for preclinical study of the tranquilizing (anxiolytic) action of drugs. In *Guidelines for Conducting Preclinical Studies of Drugs*; Part 1; Mironov, A.N., Ed.; GRIF-K: Moscow, Russia, 2012; pp. 264–275, [manual in Russian].

33. Ostrovskaya, R.U.; Raevsky, K.S.; Voronina, T.A.; Garibova, T.L.; Kovalev, G.I.; Kudrin, V.S.; Narkevich, V.B.; Kldot, P.M. Methodological recommendations for the study of neuroleptic activity of drugs. In *Guidelines for Conducting Preclinical Studies of Drugs*; Part 1; Mironov, A.N., Ed.; GRIF-K: Moscow, Russia, 2012; pp. 251–263, [manual in Russian].

34. Voronina, T.A.; Guzevatykh, L.S. Methodical recommendations for the study of the anxiolytic activity of drugs. In *Guidelines for Conducting Preclinical Studies of Drugs*; Mironov, A.N., Ed.; Part 1; GRIF-K: Moscow, Russia, 2012; pp. 197–218, [manual in Russian].

35. Harris, L.S.; Pierson, A.K. Some narcotic antagonists in the benzomorphan series. *J. Pharmacol. Exp. Ther.* 1964, 143, 141–148. [PubMed]

36. Paul, A.K.; Guven, N.; Dietis, N. Profiling the Effects of Repetitive Morphine Administration on Motor Behavior in Rats. *Molecules* 2021, 26, 4355. [CrossRef] [PubMed]

37. MarvinSketch, ChemAxonKft. Available online: http://www.chemaxon.com/products/marvin/marvinsketch/ (accessed on 27 September 2021).

38. MOPAC, Stewart Computational Chemistry. Available online: http://openmopac.net (accessed on 27 September 2021).

39. Vassiliev, P.M.; Spasov, A.A.; Yanaliyeva, L.R.; Kochetkov, A.N.; Vorfolomeyeva, V.V.; Klokchov, V.G.; Appazova, D.T. Neural network modeling of multitarget RAGE inhibitory activity. *Biochem. Moscow Suppl. Ser. B Biomed. Chem.* 2019, 13, 256–263. [CrossRef]

40. RCSB PDB, Protein Data Bank. Available online: https://www.rcsb.org/ (accessed on 27 September 2021).

41. Bergmann, R.; Kongsbak, K.; Serensen, PL.; Sander, T.; Balle, T. A Unified Model of the GABAA Receptor Comprising Agonist and Benzodiazepine Binding Sites. *PLoS ONE* 2013, 8, e52323. [CrossRef] [PubMed]

42. ModBase: Database of Comparative Protein Structure Models. Available online: https://modbase.compbio.ucsf.edu/ (accessed on 27 September 2021).

43. Trotz, O.; Olson, A.J. AutoDockVina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. *J. Comp. Chem.* 2010, 31, 455–461.

44. LigandScout, Inte: Ligand GmbH. Available online: http://www.inteligand.com/ligandscout/ (accessed on 27 September 2021).